Company news

AEON Biopharma, Inc. news in 2026

AEON Biopharma, Inc.'s news releases, calls and decks from 2026, newest first.

View company

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

August 3, 2026

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

July 14, 2026

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

June 4, 2026

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026

AEON Biopharma Sets Annual Shareholder Meeting

April 24, 2026

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

April 3, 2026

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

April 3, 2026

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

March 30, 2026

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

March 25, 2026

AEON Biopharma Appoints John Bencich as Chief Financial Officer

March 9, 2026

AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

March 5, 2026

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

January 21, 2026

Decks in 2026